Severe and critically ill patients with the novel coronavirus (COVID-19) pneumonia
Conditions
Interventions
Methylprednisolone 1-3mg/kg intravenously, d1~d7-d10+human immunoglobulin 20g/d * 5d+symptomatic treatment group:No
Methylprednisolone 1-3mg/kg intravenous drip, d1~d7-d10+symptomatic treatment group:No
Sponsors
The First Affiliated Hospital of Chongqing Medical University
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. The subjects tested positive for COVID-19 nucleic acid or antigen; 2. Aged >=18 years; 3. According to the tenth edition of the Diagnosis and Treatment Protocol for COVID-19 patients with severe and critical Pneumonia are clinically classified; 4. Voluntary written informed consent.
Exclusion criteria
Exclusion criteria: 1. Definited allergy to methylprednisolone and immunoglobulin; 2. Basic complicated with severe hematological diseases (leukemia, aplastic disorder, thalassemia, etc.) or autoimmune diseases (systemic lupus erythematosus, scleroderma, rheumatoid arthritis, etc.); 3. Immunodeficient patients (such as AIDS patients, organ or bone marrow transplants, immune dysfunction caused by long-term using corticosteroids or other immunosuppressive medicine); 4. Other conditions unsuitable for this study by the researchers.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Immunoinflammation; | — |
Secondary
| Measure | Time frame |
|---|---|
| Clinical outcome;Single-cell multiomics; | — |
Countries
China
Contacts
Public ContactYang Li
The First Affiliated Hospital of Chongqing Medical University
Outcome results
None listed